Barriers of hepatitis C virus interspecies transmission

Virology

Volumn 435, Issue 1, 2013, Pages 70-80

  Sandmann, Lisa ^a   Ploss, Alexander ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Animal models; Drug development; Hepatitis C virus; Humanized mice; Pathogenesis; Species tropism; Vaccine development

Indexed keywords

ANTIVIRAL ACTIVITY; CELL FUSION; CHIMPANZEE; DISEASE PREDISPOSITION; EVOLUTIONARY ADAPTATION; EXPERIMENTAL MODEL; EXPERIMENTAL MONKEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA REPLICATION; RNA TRANSLATION; SPECIES COMPARISON; TRANSGENIC MOUSE; VIROGENESIS; VIRUS ASSEMBLY; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS RELEASE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS UNCOATING; VIRUS VIRULENCE; XENOTRANSPLANTATION;

ANIMALS; CELL CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST SPECIFICITY; HUMANS; MICE; MICE, TRANSGENIC; PAN TROGLODYTES; RNA, VIRAL; VIRUS INTERNALIZATION; VIRUS REPLICATION;

ANIMALIA; HEPATITIS C VIRUS; MUS; PAN;

EID: 84870659645     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.09.044     Document Type: Review

References (137)

1. Abe K., Kurata T., Teramoto Y., Shiga J., Shikata T. Lack of susceptibility of various primates and woodchucks to hepatitis C virus. J. Med. Primatol. 1993, 22:433-434.
2. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyer S.P., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
3. Amako Y., Tsukiyama-Kohara K., Katsume A., Hirata Y., Sekiguchi S., Tobita Y., Hayashi Y., Hishima T., Funata N., Yonekawa H., Kohara M. Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J. Virol. 2010, 84:303-311.
4. Andrus L., Marukian S., Jones C.T., Catanese M.T., Sheahan T.P., Schoggins J.W., Barry W.T., Dustin L.B., Trehan K., Ploss A., Bhatia S.N., Rice C.M. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 2011, 54:1901-1912.
5. Bartenschlager R., Penin F., Lohmann V., Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011, 19:95-103.
6. Berger K.L., Cooper J.D., Heaton N.S., Yoon R., Oakland T.E., Jordan T.X., Mateu G., Grakoui A., Randall G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7577-7582.
7. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 2004, 5:1109-1115.
8. Bissig K.D., Wieland S.F., Tran P., Isogawa M., Le T.T., Chisari F.V., Verma I.M. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 2010, 120:924-930.
9. Bitzegeio J., Bankwitz D., Hueging K., Haid S., Brohm C., Zeisel M.B., Herrmann E., Iken M., Ott M., Baumert T.F., Pietschmann T. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog. 2010, 6:e1000978.
10. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972-1974.
11. Blight K.J., McKeating J.A., Rice C.M. Highly permissive cell lines for hepatitis C virus genomic and subgenomic RNA replication. J. Virol. 2002, 76:13001-13014.
12. Borawski J., Troke P., Puyang X., Gibaja V., Zhao S., Mickanin C., Leighton-Davies J., Wilson C.J., Myer V., Cornellataracido I., Baryza J., Tallarico J., Joberty G., Bantscheff M., Schirle M., Bouwmeester T., Mathy J.E., Lin K., Compton T., Labow M., Wiedmann B., Gaither L.A. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 2009, 83:10058-10074.
13. Brenndorfer E.D., Karthe J., Frelin L., Cebula P., Erhardt A., Schulte am Esch J., Hengel H., Bartenschlager R., Sallberg M., Haussinger D., Bode J.G. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 2009, 49:1810-1820.
14. Bukh J., Apgar C.L., Govindarajan S., Purcell R.H. Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees. J. Med. Virol. 2001, 65:694-697.
15. Burbelo P.D., Dubovi E.J., Simmonds P., Medina J.L., Henriquez J.A., Mishra N., Wagner J., Tokarz R., Cullen J.M., Iadarola M.J., Rice C.M., Lipkin W.I., Kapoor A. Serology-enabled discovery of genetically diverse hepaciviruses in a new host. J. Virol. 2012, 86:6171-6178.
16. Chang J., Nicolas E., Marks D., Sander C., Lerro A., Buendia M.A., Xu C., Mason W.S., Moloshok T., Bort R., Zaret K.S., Taylor J.M. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004, 1:106-113.
17. Chang K.S., Cai Z., Zhang C., Sen G.C., Williams B.R., Luo G. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J. Virol. 2006, 80:7364-7374.
18. Chen A.A., Thomas D.K., Ong L.L., Schwartz R.E., Golub T.R., Bhatia S.N. Humanized mice with ectopic artificial liver tissues. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11842-11847.
19. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362.
20. Coelmont L., Kaptein S., Paeshuyse J., Vliegen I., Dumont J.M., Vuagniaux G., Neyts J. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob. Agents Chemother. 2009, 53:967-976.
21. Coller K.E., Berger K.L., Heaton N.S., Cooper J.D., Yoon R., Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009, 5:e1000702.
22. Cormier E.G., Durso R.J., Tsamis F., Boussemart L., Manix C., Olson W.C., Gardner J.P., Dragic T. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14067-14072.
23. de Jong Y.P., Rice C.M., Ploss A. New horizons for studying human hepatotropic infections. J. Clin. Invest. 2010, 120:650-653.
24. Deinhardt F., Holmes A.W., Capps R.B., Popper H. Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passages, and description of liver lesions. J. Exp. Med. 1967, 125:673-688.
25. Diao J., Pantua H., Ngu H., Komuves L., Diehl L., Schaefer G., Kapadia S.B. Hepatitis C Virus (HCV) induces Epidermal Growth Factor Receptor (EGFR) activation via CD81 binding for viral internalization and entry. J. Virol. 2012.
26. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., Jones C.T., Schoggins J.W., Catanese M.T., Burton D.R., Law M., Rice C.M., Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
27. Dorner, M., Rice, C.M., Ploss, A. Study of hepatitis C virusentry in genetically humanized mice. Methods , in press. http://dx.doi.org/10.1016/j.ymeth.2012.05.010.
28. Edlin B.R. Perspective: test and treat this silent killer. Nature 2011, 474:S18-S19.
29. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
30. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., Mushahwar I.K., Desai S.M., Miller R.H., Ogata N., Purcell R.H. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258:135-140.
31. Flint M., von Hahn T., Zhang J., Farquhar M., Jones C.T., Balfe P., Rice C.M., McKeating J.A. Diverse CD81 proteins support hepatitis C virus infection. J. Virol. 2006, 80:11331-11342.
32. Frentzen A., Huging K., Bitzegeio J., Friesland M., Haid S., Gentzsch J., Hoffmann M., Lindemann D., Zimmer G., Zielecki F., Weber F., Steinmann E., Pietschmann T. Completion of Hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines. PLoS Pathog. 2011, 7:e1002029.
33. Gardner J.P., Durso R.J., Arrigale R.R., Donovan G.P., Maddon P.J., Dragic T., Olson W.C. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4498-4503.
34. Garson J.A., Whitby K., Watkins P., Morgan A.J. Lack of susceptibility of the cottontop tamarin to hepatitis C infection. J. Med. Virol. 1997, 52:286-288.
35. Giang E., Dorner M., Prentoe J.C., Dreux M., Evans M.J., Bukh J., Rice C.M., Ploss A., Burton D.R., Law M. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6205-6210.
36. Gottwein E., Cullen B.R. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microb. 2008, 3:375-387.
37. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., Walker C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659-662.
38. Grompe M., al-Dhalimy M., Finegold M., Ou C.N., Burlingame T., Kennaway N.G., Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 1993, 7:2298-2307.
39. Heckel J.L., Sandgren E.P., Degen J.L., Palmiter R.D., Brinster R.L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990, 62:447-456.
40. Hikosaka K., Noritake H., Kimura W., Sultana N., Sharkar M.T., Tagawa Y., Uezato T., Kobayashi Y., Wakita T., Miura N. Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry. Biomed. Res. 2011, 32:143-150.
41. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. J. Hepatol. 2009, 51:939-948.
42. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 2011, 239:99-108.
43. Huang H., Sun F., Owen D.M., Li W., Chen Y., Gale M., Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5848-5853.
44. Ilan E., Arazi J., Nussbaum O., Zauberman A., Eren R., Lubin I., Neville L., Ben Moshe O., Kischitzky A., Litchi A., Margalit I., Gopher J., Mounir S., Cai W., Daudi N., Eid A., Jurim O., Czerniak A., Galun E., Dagan S. The hepatitis C virus (HCV)-trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis. 2002, 185:153-161.
45. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
46. Jones C.T., Catanese M.T., Law L.M., Khetani S.R., Syder A.J., Ploss A., Oh T.S., Schoggins J.W., MacDonald M.R., Bhatia S.N., Rice C.M. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 2010, 28:167-171.
47. Jones D.M., Domingues P., Targett-Adams P., McLauchlan J. Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J. Gen. Virol. 2010, 91:2238-2248.
48. Jopling C.L., Schutz S., Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microb. 2008, 4:77-85.
49. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
50. Kapoor A., Simmonds P., Gerold G., Qaisar N., Jain K., Henriquez J.A., Firth C., Hirschberg D.L., Rice C.M., Shields S., Lipkin W.I. Characterization of a canine homolog of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11608-11613.
51. Karayiannis P., Petrovic L.M., Fry M., Moore D., Enticott M., McGarvey M.J., Scheuer P.J., Thomas H.C. Studies of GB hepatitis agent in tamarins. Hepatology 1989, 9:186-192.
52. Kaul A., Stauffer S., Berger C., Pertel T., Schmitt J., Kallis S., Zayas M., Lohmann V., Luban J., Bartenschlager R. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009, 5:e1000546.
53. Khetani S.R., Bhatia S.N. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 2008, 26:120-126.
54. Klotman P.E., Notkins A.L. Transgenic models of human immunodeficiency virus type-1. Curr. Top. Microbiol. Immunol. 1996, 206:197-222.
55. Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997, 277:570-574.
56. Kurano M., Hara M., Tsuneyama K., Okamoto K., Iso O.N., Matsushima T., Koike K., Tsukamoto K. Modulation of lipid metabolism with the over-expression of NPC1L1 in mice liver. J. Lipid Res. 2012, 53:2275-2285.
57. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D., Davis M.N., Galati J.S., Gordon S.C., Ravendhran N., Rossaro L., Anderson F.H., Jacobson I.M., Rubin R., Koury K., Pedicone L.D., Brass C.A., Chaudhri E., Albrecht J.K. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
58. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bös M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagacé L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St.George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., Llinàs-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
59. Lanford R.E., Chavez D., Notvall L., Brasky K.M. Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. Virology 2003, 311:72-80.
60. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
61. Lassnig C., Kolb A., Strobl B., Enjuanes L., Muller M. Studying human pathogens in animal models: fine tuning the humanized mouse. Transgenic Res. 2005, 14:803-806.
62. Lecuit M., Vandormael-Pournin S., Lefort J., Huerre M., Gounon P., Dupuy C., Babinet C., Cossart P. A transgenic model for listeriosis: role of internalin in crossing the intestinal barrier. Science 2001, 292:1722-1725.
63. Legrand N., Ploss A., Balling R., Becker P.D., Borsotti C., Brezillon N., Debarry J., de Jong Y., Deng H., Di Santo J.P., Eisenbarth S., Eynon E., Flavell R.A., Guzman C.A., Huntington N.D., Kremsdorf D., Manns M.P., Manz M.G., Mention J.J., Ott M., Rathinam C., Rice C.M., Rongvaux A., Stevens S., Spits H., Strick-Marchand H., Takizawa H., van Lent A.U., Wang C., Weijer K., Willinger T., Ziegler P. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microb. 2009, 6:5-9.
64. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., Ray S.C., Gale M., Lemon S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2992-2997.
65. Li Q., Brass A.L., Ng A., Hu Z., Xavier R.J., Liang T.J., Elledge S.J. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16410-16415.
66. Lin L.T., Noyce R.S., Pham T.N., Wilson J.A., Sisson G.R., Michalak T.I., Mossman K.L., Richardson C.D. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J. Virol. 2010, 84:9170-9180.
67. Liu S., Yang W., Shen L., Turner J.R., Coyne C.B., Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009, 83:2011-2014.
68. Lohmann V., Korner F., Koch J.O., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
69. Long G., Hiet M.S., Windisch M.P., Lee J.Y., Lohmann V., Bartenschlager R. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 2011, 141(3):1057-1066.
70. Lozach P.Y., Lortat-Jacob H., de Lacroix de Lavalette A., Staropoli I., Foung S., Amara A., Houles C., Fieschi F., Schwartz O., Virelizier J.L., Arenzana-Seisdedos F., Altmeyer R. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 2003, 278:20358-20366.
71. Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., McKeating J.A., Brino L., Baumert T.F. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011, 17:589-595.
72. Machlin E.S., Sarnow P., Sagan S.M. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3193-3198.
73. Mancone C., Steindler C., Santangelo L., Simonte G., Vlassi C., Longo M.A., D'Offizi G., Di Giacomo C., Pucillo L.P., Amicone L., Tripodi M., Alonzi T. Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins. Gut 2011, 60:378-386.
74. Martin, D.N., Uprichard, S., 2010. The role of transferrin receptor in Hepatitis C virus entry. In: Proceedings of the 18th International Symposium on Hepatitis C Virus & Related Viruses, Yokohama, Japan.
75. Marukian S., Andrus L., Sheahan T.P., Jones C.T., Charles E.D., Ploss A., Rice C.M., Dustin L.B. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology 2011, 54(6):1913-1923.
76. Masciopinto F., Freer G., Burgio V.L., Levy S., Galli-Stampino L., Bendinelli M., Houghton M., Abrignani S., Uematsu Y. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 2002, 304:187-196.
77. McCaffrey A.P., Ohashi K., Meuse L., Shen S., Lancaster A.M., Lukavsky P.J., Sarnow P., Kay M.A. Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol. Ther. 2002, 5:676-684.
78. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., McNair L., Alam J., Muir A.J. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360:1827-1838.
79. Meertens L., Bertaux C., Cukierman L., Cormier E., Lavillette D., Cosset F.L., Dragic T. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J. Virol. 2008, 82:3555-3560.
80. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001, 7:927-933.
81. Merz A., Long G., Hiet M.S., Brugger B., Chlanda P., Andre P., Wieland F., Krijnse-Locker J., Bartenschlager R. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J. Biol. Chem. 2011, 286:3018-3032.
82. Meuleman P., Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antivir. Res 2008, 80(3):231-238.
83. Meuleman P., Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antivir. Res. 2008, 80:231-238.
84. Meuleman P., Libbrecht L., De Vos R., de Hemptinne B., Gevaert K., Vandekerckhove J., Roskams T., Leroux-Roels G. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005, 41:847-856.
85. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
86. Michta M.L., Hopcraft S.E., Narbus C.M., Kratovac Z., Israelow B., Sourisseau M., Evans M.J. Species-specific regions of occludin required by hepatitis C virus for cell entry. J. Virol. 2010, 84:11696-11708.
87. Ng T.I., Mo H., Pilot-Matias T., He Y., Koev G., Krishnan P., Mondal R., Pithawalla R., He W., Dekhtyar T., Packer J., Schurdak M., Molla A. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007, 45:1413-1421.
88. Nielsen S.U., Bassendine M.F., Burt A.D., Martin C., Pumeechockchai W., Toms G.L. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 2006, 80:2418-2428.
89. NIH, 2011. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-025.htm.
90. Nitta, S., Sakamoto, N., Nakagawa, M., Kakinuma, S., Mishima, K., Kusano-Kitazume, A., Kiyohashi, K., Murakawa, M., Nishimura-Sakurai, Y., Azuma, S., Tasaka-Fujita, M., Asahina, Y., Yoneyama, M., Fujita, T., Watanabe, M. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immunity. Hepatology , in press. http://dx.doi.org/10.1002/hep.26017.
91. Olsen D.B., Davies M.E., Handt L., Koeplinger K., Zhang N.R., Ludmerer S.W., Graham D., Liverton N., MacCoss M., Hazuda D., Carroll S.S. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob. Agents Chemother. 2011, 55:937-939.
92. Patel M.R., Loo Y.M., Horner S.M., Gale M., Malik H.S. Convergent evolution of escape from hepaciviral antagonism in primates. PLoS Biol. 2012, 10:e1001282.
93. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45:529-538.
94. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
95. Ploss A., Evans M.J. Hepatitis C virus host cell entry. Curr. Opin. Virol. 2012, 2:14-19.
96. Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P., Rice C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-886.
97. Ploss A., Khetani S.R., Jones C.T., Syder A.J., Trehan K., Gaysinkaya V.A., Mu K., Ritola K., Rice C.M., Bhatia S.N. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc. Natl. Acad. Sci. USA 2010, 107:3141-3145.
98. Pohlmann S., Zhang J., Baribaud F., Chen Z., Leslie G.J., Lin G., Granelli-Piperno A., Doms R.W., Rice C.M., McKeating J.A. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 2003, 77:4070-4080.
99. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy K.R., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J.P. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1195-1206.
100. Prince A., Brotman B., Huima T., Pascual D., Jaffery M., Inchauspé G. Immunity in hepatitis C infection. J. Infect. Dis. 1992, 165:438-443.
101. Racaniello V.R., Ren R. Transgenic mice and the pathogenesis of poliomyelitis. Arch. Virol. Suppl 1994, 9:79-86.
102. Randall G., Panis M., Cooper J.D., Tellinghuisen T.L., Sukhodolets K.E., Pfeffer S., Landthaler M., Landgraf P., Kan S., Lindenbach B.D., Chien M., Weir D.B., Russo J.J., Ju J., Brownstein M.J., Sheridan R., Sander C., Zavolan M., Tuschl T., Rice C.M. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12884-12889.
103. Reiss S., Rebhan I., Backes P., Romero-Brey I., Erfle H., Matula P., Kaderali L., Poenisch M., Blankenburg H., Hiet M.S., Longerich T., Diehl S., Ramirez F., Balla T., Rohr K., Kaul A., Buhler S., Pepperkok R., Lengauer T., Albrecht M., Eils R., Schirmacher P., Lohmann V., Bartenschlager R. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microb. 2011, 9:32-45.
104. Roelandt P., Obeid S., Paeshuyse J., Vanhove J., Van Lommel A., Nahmias Y., Nevens F., Neyts J., Verfaillie C.M. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J. Hepatol. 2012, 57:246-251.
105. Sainz B., Barretto N., Martin D.N., Hiraga N., Imamura M., Hussain S., Marsh K.A., Yu X., Chayama K., Alrefai W.A., Uprichard S.L. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 2012, 18:281-285.
106. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
107. Schaluder G.G., Dawson G.J., Simons J.N., Pilot-Matias T.J., Gutierrez R.A., Heynen C.A., Knigge M.F., Kurpiewski G.S., Buijk S.L., Leary T.P., et al. Molecular and serologic analysis in the transmission of the GB hepatitis agents. J. Med. Virol. 1995, 46:81-90.
108. Schmitz J., Ohme M., Zischler H. The complete mitochondrial genome of Tupaia belangeri and the phylogenetic affiliation of scandentia to other eutherian orders. Mol. Biol. Evol. 2000, 17:1334-1343.
109. Schoggins J.W., Rice C.M. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 2011, 1:519-525.
110. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
111. Schwartz R.E., Trehan K., Andrus L., Sheahan T.P., Ploss A., Duncan S.A., Rice C.M., Bhatia S.N. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2544-2548.
112. Sellin C.I., Horvat B. Current animal models: transgenic animal models for the study of measles pathogenesis. Curr. Top. Microbiol. Immunol. 2009, 330:111-127.
113. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., Walker C.M. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 2003, 197:1645-1655.
114. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
115. Simons J.N., Leary T.P., Dawson G.J., Pilot-Matias T.J., Muerhoff A.S., Schlauder G.G., Desai S.M., Mushahwar I.K. Isolation of novel virus-like sequences associated with human hepatitis. Nat. Med. 1995, 1:564-569.
116. Sithebe N.P., Kew M.C., Mphahlele M.J., Paterson A.C., Lecatsas G., Kramvis A., de Klerk W. Lack of susceptibility of Chacma baboons (Papio ursinus orientalis) to hepatitis C virus infection. J. Med. Virol. 2002, 66:468-471.
117. Supekova L., Supek F., Lee J., Chen S., Gray N., Pezacki J.P., Schlapbach A., Schultz P.G. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J. Biol. Chem. 2008, 283:29-36.
118. Tai A.W., Benita Y., Peng L.F., Kim S.S., Sakamoto N., Xavier R.J., Chung R.T. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microb. 2009, 5:298-307.
119. Temel R.E., Tang W., Ma Y., Rudel L.L., Willingham M.C., Ioannou Y.A., Davies J.P., Nilsson L.M., Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 2007, 117:1968-1978.
120. Trotard M., Lepere-Douard C., Regeard M., Piquet-Pellorce C., Lavillette D., Cosset F.L., Gripon P., Le Seyec J. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J. 2009, 23:3780-3789.
121. Uprichard S.L., Chung J., Chisari F.V., Wakita T. Replication of a hepatitis C virus replicon clone in mouse cells. Virol. J. 2006, 3:89.
122. Vaillancourt F.H., Pilote L., Cartier M., Lippens J., Liuzzi M., Bethell R.C., Cordingley M.G., Kukolj G. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 2009, 387:5-10.
123. Vernachio J.H., Bleiman B., Bryant K.D., Chamberlain S., Hunley D., Hutchins J., Ames B., Gorovits E., Ganguly B., Hall A., Kolykhalov A., Liu Y., Muhammad J., Raja N., Walters C.R., Wang J., Williams K., Patti J.M., Henson G., Madela K., Aljarah M., Gilles A., McGuigan C. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob. Agents Chemother. 2011, 55:1843-1851.
124. Wang F., Ma Y., Barrett J.W., Gao X., Loh J., Barton E., Virgin H.W., McFadden G. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. 2004, 5:1266-1274.
125. Washburn, M.L., Bility, M.T., Zhang, L., Kovalev, G.I., Buntzman, A., Frelinger, J.A., Barry, W., Ploss, A., Rice, C.M., Su, L., 2011. A humanized mouse model to study Hepatitis C virus infection, immune response, and liver disease. Gastroenterology. 140 (4), 1334-1344.
126. Willinger T., Rongvaux A., Strowig T., Manz M.G., Flavell R.A. Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends Immunol. 2011, 32:321-327.
127. Wong-Staal, F., Chang, J., Rijnbrand, R., Shin, C., Lee, H., Syder, A.J., Yang, J.P., 2008. Characterization of the role of the protocadherin B famility in HCV entry. In: Proceedings of the 16th International Symposium on Hepatitis C Virus & Related Viruses, San Antonio, TX, USA.
128. Wu X., Robotham J.M., Lee E., Dalton S., Kneteman N.M., Gilbert D.M., Tang H. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog. 2012, 8:e1002617.
129. Xie Z.C., Riezu-Boj J.I., Lasarte J.J., Guillen J., Su J.H., Civeira M.P., Prieto J. Transmission of hepatitis C virus infection to tree shrews. Virology 1998, 244:513-520.
130. Xu L., Chen S.Y., Nie W.H., Jiang X.L., Yao Y.G. Evaluating the phylogenetic position of Chinese tree shrew (Tupaia belangeri chinensis) based on complete mitochondrial genome: implication for using tree shrew as an alternative experimental animal to primates in biomedical research. J. Genet. Genomics=Yi chuan xue bao 2012, 39:131-137.
131. Xu X., Chen H., Cao X., Ben K. Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma. J. Gen. Virol. 2007, 88:2504-2512.
132. Yang F., Robotham J.M., Nelson H.B., Irsigler A., Kenworthy R., Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 2008, 82:5269-5278.
133. Yang P.L., Gao M., Lin K., Liu Q., Villareal V.A. Anti-HCV drugs in the pipeline. Curr. Opin. Virol. 2011, 1:607-616.
134. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 2007, 3:e108.
135. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004, 5:730-737.
136. Zheng A., Yuan F., Li Y., Zhu F., Hou P., Li J., Song X., Ding M., Deng H. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J. Virol. 2007, 81:12465-12471.
137. Zhu Q., Guo J.T., Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J. Virol. 2003, 77:9204-9210.